Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a p...

Read More

PHAT Performance At-A-Glance

RISK EFFICIENCY

-0.47

Phathom Pharmaceuticals, Inc.'s risk efficiency is -0.47, which is poor. By comparison, the S&P500 is -0.5.

Increasing quickly  over the past 4 weeks.

DSCORE

9.65%

Phathom Pharmaceuticals, Inc.'s dScore is 9.65% , which is more volatile than the S&P500 (2.74%).

Increasing slightly over the past 4 weeks.

GROWTH

-56.37%

Phathom Pharmaceuticals, Inc. has shrunk by -56.37% over the past year.  By comparison, the S&P500 has lost -12.78%.